Early Laboratory Packet Diagnosis for Successful Fighting MDS and AML (ITP and LGC)

Abstract: RNAi induce variable mutation which the prevalence is very high nowadays, ever diagnose Large Granular Chronic (LGC) patients. Problem: High prevalence of mortality cases in ITP, MDS, and AML in which the complaint is only nausea/ vomitus, bloated, fatigue or lethargic, and progress to deadly ITP/AML we meet in everyday practice. Anemia and thrombocytopenia progress to death of ITP/AML in 2 weeks- 5 months after first time hospitalized to get transfusion and dextrose 5% infusion for the used-up energy/ glycogen in the liver. The laboratory packet should support “bridge therapy” to surgery or invasive procedure, splenectomy and or chemotherapy. Method: Case report and review of my Library recommendation of Google Scholar, ChatGPT, elaborate to ScienceDirect and EBSCOHost MEDLINE full text. Recorded all the Laboratory found in the case report and references. Result: Case Report and References of Dx/ associated with phases of ITP/MDS/AML. Discussion: Laboratory of the symptoms in each phase ITP and MDS/AML. Conclusion: Complex biomarker vs. simple laboratory packet in early RNAi induce ITP and AML in the mapping of ITP/AML phase to fight high mortality, stay calm with right nutrition to support the body metabolism of ITP progression to AML/ MDS. High Protein Low Carbohydrate on low Albumin plasma is already built-in in all phases.